Australia markets close in 4 hours 19 minutes

Telix Pharmaceuticals Limited (TLX.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
4.5200-0.2300 (-4.84%)
As of 11:32AM AEST. Market open.
Full screen
Previous close4.7500
Open4.6000
Bid4.5200 x 993000
Ask4.5300 x 862200
Day's range4.4400 - 4.6500
52-week range3.5500 - 8.8200
Volume331,163
Avg. volume890,882
Market cap1.414B
Beta (5Y monthly)2.28
PE ratio (TTM)N/A
EPS (TTM)-0.2850
Earnings date17 Aug 2022 - 22 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.15
  • PR Newswire

    Telix and Invicro Advance AI Partnership

    Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has advanced a partnership with Invicro LLC (Invicro), a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to develop an artificial intelligence (AI) platform to accompany Telix's PSMA-PET[1] imaging agent, Illuccix® (kit for the preparation of gallium Ga 68 gozetotide) - known as TelixAITM.

  • PR Newswire

    Jubilant Radiopharma Joins Illuccix® Pharmacy Partner Network

    Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga 68 gozetotide), is now available at selected pharmacies in the Jubilant Radiopharma network. Illuccix is now available to order from 139 pharmacy sites across the United States, ensuring scheduling flexibility and patient access to advanced prostate cancer imaging.

  • PR Newswire

    Telix and RefleXion Expand Partnership for Prostate Cancer Treatment

    Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. (Hayward, California, U.S.) (RefleXion) today announced the signing of a co-development and commercialisation agreement, to expand the use of Telix's prostate cancer imaging agent, Illuccix® (kit for preparation of gallium (68Ga) gozetotide) with the RefleXion® biology-guided radiotherapy (BgRT)* platform to guide external-beam radiotherapy in real-time.